CN Patent

CN116583540A — 用于治疗her2癌症的组合疗法

Assigned to F Hoffmann La Roche AG · Expires 2023-08-11 · 3y expired

What this patent protects

本发明提供用于治疗HER2阳性癌症的组合疗法，所述组合疗法包含inavolisib(又名GDC‑0077)和其他HER2靶向疗法(例如，帕妥珠单抗和曲妥珠单抗)；以及治疗患者(优选为患有PIK3CA突变型乳腺癌的患者)的HER2阳性(HER2+)癌症的方法，所述方法包括施用治疗有效量的inavolisib和HER2靶向疗法(例如，曲妥珠单抗，帕妥珠单抗，或曲妥珠单抗与帕妥珠单抗的组合)。

USPTO Abstract

本发明提供用于治疗HER2阳性癌症的组合疗法，所述组合疗法包含inavolisib(又名GDC‑0077)和其他HER2靶向疗法(例如，帕妥珠单抗和曲妥珠单抗)；以及治疗患者(优选为患有PIK3CA突变型乳腺癌的患者)的HER2阳性(HER2+)癌症的方法，所述方法包括施用治疗有效量的inavolisib和HER2靶向疗法(例如，曲妥珠单抗，帕妥珠单抗，或曲妥珠单抗与帕妥珠单抗的组合)。

Drugs covered by this patent

Patent Metadata

Patent number
CN116583540A
Jurisdiction
CN
Classification
—
Expires
2023-08-11
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.